Endocrine Abstracts

Background: The PCSK9 inhibitors (PCSKi), evolocumab and alirocumab, were approved by NICE in 2016, and have since proved to be efficacious in lowering LDL-C. Yet little is known about their long-term adverse effects. Genetic studies have shown patients with PCSK9 loss-of-function variants are at increased risk of T2DM. Similarly, analyses of an adverse event database found increased reports of PCSK9i-related hyperglycaemia. Meta-analyses have suggested that P...